Navigation Links
NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/15/2008

SAN MATEO, Calif., May 15 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present on Monday, May 19, 2008 at the Rodman & Renshaw 5th Annual Global Healthcare Conference. Anthony DiTonno, President and Chief Executive Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions.

Event: Rodman & Renshaw 5th Annual Global Healthcare Conference

Date: Monday, May 19, 2008

Time: 5:15 p.m. CEST

Place: Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco

An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX Reports First Quarter 2008 Results
2. NeurogesX to Report First Quarter 2008 Financial Results
3. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
6. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
7. NeurogesX Closes $25 Million Private Placement
8. NeurogesX, Inc. Announces $25 Million Private Placement
9. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
10. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. NeurogesX Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... LAFAYETTE, Ind. A new research platform ... properties of tiny structures undergoing stress and ... to improve designs for microelectronics and batteries., ... reveals information about how heating and the ... mechanical properties. Researchers have discussed the merits ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... 10 Corthera Inc. today,announced that an interim ... portion of a Phase II/III multicenter, randomized, double-blind,international ... the,company,s investigational drug for treatment of acute heart ... presented by John R. Teerlink, M.D.,Professor of Medicine, ...
... 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company focused ... in China,today announced that it has filed with ... approval of NuLeusin for the treatment of late,stage ... expected to,be the only treatment of this kind ...
... today,announced financial results for the second quarter ended September ... quarter, representing an,increase of 27.1% from 100.9 billion yen ... results of PENTAX included in the scope of,consolidation during ... billion yen, a 23.2% decrease compared with,26.8 billion yen ...
Cached Biology Technology:Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 2Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 33SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4Hoya Announces Second Quarter and First Half Financial Results for FY2008 2
(Date:9/1/2014)... the Nomenclature Section of the XVIII International Botanical Congress ... meeting is held every six years and it is ... naming algae, fungi and plants get together to debate ... they study. This is the primary product of the ... and plants, which was published in 2012. The other ...
(Date:8/31/2014)... go after each other. But when viruses invade bacteria, ... Sometimes viruses actually carry helpful genes that a bacterium ... attack its own hosts. , Scientists have assumed the ... anything it recognized as invading viral genes. However, new ... variety of the bacterial immune system known as the ...
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3The early cost of HIV 2
... -- Zeroing in on the early cell mutations that enable a ... a personalized therapy to stop it. Scientists were able to use ... order in which these abnormalities form to analyze the pattern of ... findings, which are published in the July edition of Cancer ...
... 29, 2011 BD Biosciences, a segment of ... availability of BD Recharge™, a chemically defined (CD) ... offers productivity comparable to yeast-based peptones. ... for biopharmaceutical cell culture," said Robert Hallenbeck, Vice ...
... uncovered half-a-billion-year-old fossils demonstrating that primitive animals had excellent vision. ... South Australian Museum and the University of Adelaide ... from a recently swatted fly. This discovery will be ... Nature . The lead author is ...
Cached Biology News:Scientists develop method to determine order of mutations that lead to cancer 2BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2New fossils demonstrate that powerful eyes evolved in a twinkling 2
... The EZ DNA Methylation Kit uses a ... for DNA methylation analysis. The kit is ... takes place between cytosine and sodium bisulfite ... EZ DNA Methylation Kits innovative in-column desulphonation ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... EIA Principle: The ... LTE4 are products of arachidonic ... glutathione-S-transferase. In the past, they ... Substances of Anaphylaxis (SRS-A)". They ...
Biology Products: